Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Cervical cancer vaccine `in five years'

Maxine Frith Social Affairs Correspondent
Wednesday 02 February 2005 01:02 GMT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A VACCINE for cervical cancer will be available within five years, a leading scientist has predicted. Trials of the injection are advanced and have been highly successful, said Anne Szarewski, who is leading the race to produce a preventive treatment.

But she said the fact that the vaccine protected against a sexually transmitted disease that can lead to cervical cancer could deter parents from allowing their daughters to have it.

Up to 70 per cent of cervical cancers are caused by the sexually transmitted human papillomavirus (HPV). While three- quarters of sexually active women and men are exposed to HPV at some point, most have no symptoms. In 1 to 2 per cent of cases, it can cause abnormalities that may become cancer.

Dr Szarewski said: "I think there will be a huge political issue about vaccinating young girls against what is effectively a sexually transmitted infection, and all the parental concerns."

GlaxoSmithKline (GSK), with whom Dr Szarewski is working, and Merck are developing rival vaccines. Both mimick strains of HPV which stimulate a response from the body's immune system against the virus. Dr Szarewski said: "I suspect we will have a vaccine within the next five years."

About 3,000 women in Britain are diagnosed with cervical cancer each year and a third die. It is the second most common cancer in women under the age of 25 in the UK. Worldwide, it is the second most common cause of cancer death in women of all ages

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in